Dosing will be a key success factor in repurposing antivirals for COVID‐19

This commentary highlights the need for the collection of data which will be required to prioritise and evaluate potential repurposed drug candidates, and to design COVID‐19 targeted dosing which specifically address the challenges associated with treating this disease.


British Journal of Clinical Pharmacology